黃晞華先生 Meihao Medical Group Co., Ltd 美皓醫療集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1947） 董事名單與其角色職能 美 皓 醫 療 集 團 有 限 公 司（「本公司」）董 事（「董 事」）會（「董事會」）成 員 載 列 如 下： 執行董事 王曉敏先生 （主 席） 周健醫生 獨立非執行董事 譚漢珊女士 張永存先生 董 事 會 下 設 三 個 委 員 會，該 等 委 員 會 的 成 員 載 列 如 下： | | 董事委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | --- | | 董 事 | | | | | | 王曉敏先生 | | – | M | C | | 周健醫生 | | – | – | – | | 黃晞華先生 | | C | M | – | | 譚漢珊女士 | | M | C | M | | 張永存先生 | | M | – | M | 附 註： C: 有關董事委員會的主席 M: 有關董事委員會的成員 中 國 溫 州，二 零 二 五 年 六 月 十 八 日 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Meihao Medical Group Co., Ltd | | | | | | | 普通決議案 | | | | | | | | 所投票數及概約百分比(%) | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | | | | | | | 贊 成 反 對 | | 1. | 省 | 覽、考 | 慮 | | 及 採 | 納 本 | 公 | 司 截 | 至 | 二 | 零 | 二 | 四 | 349,610,000 0 | | | | | | | | 年十二月三十一日止年度的經審核綜 | | | | | | | | (100%) (0%) | | | 合 | 財 務 | 報 | | 表、董 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 通 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Meihao Medical Group Co., Ltd 作為普通決議案 – 1 – 1. 省覽及採納本公司截至二零二四年十二月三十一日止年度的經審核綜合 財 務 報 表、董 事（「董 事」）會 報 告 及 核 數 師 報 告。 2. (i) 重 選 鄭 蠻 女 士 為 執 行 董 事。 (ii) 重 選 黃 晞 華 先 生 為 獨 立 非 執 行 董 事。 (iii) 重 選 張 永 存 先 生 為 獨 立 非 執 行 董 事。 (iv) 授 權 董 事 會（「董事會」）釐 定 董 事 薪 酬。 3. 續 聘 安 永 會 計 師 事 務 所 為 核 數 師，並 授 權 董 事 會 釐 定 其 薪 酬。 美皓醫療集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1947） ...

此乃要件 請即處理 閣下如對本通函任何方面或將採取之行動有任何疑問，應諮詢 閣下的股票經紀或其他持牌證券交易 商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已將名下的美皓醫療集團有限公司的股份全部出售或轉讓，應立即將本通函連同隨附之代表委 任表格送交買主或承讓人，或經手買賣或轉讓的銀行、股票經紀或其他代理商，以便轉交買主或承讓 人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部份內容而產生或因倚賴該等內容而 引致的任何損失承擔任何責任。 Meihao Medical Group Co., Ltd 美皓醫療集團有限公司 （股份代號：1947） （於開曼群島註冊成立的有限公司） 建議 授予發行股份及購回股份之一般授權、 重選董事 及 股東週年大會通告 除文義另有所指外，本封面頁採用之詞彙與本通函「釋義」一節所界定者具有相同涵義。 美皓醫療集團有限公司謹訂於二零二五年六月十八日（星期三）上午十時正假座中國浙江省溫州市鹿城 區江濱西路352號株浦大廈5樓會議室舉行股東週年大會，會上將考慮（其中包括）上述建議 ...

Financial Performance - The company reported a slight revenue increase from RMB 735 million to RMB 747 million compared to 2023, despite a challenging market environment[11]. - The group's revenue for the year ended December 31, 2024, was approximately RMB 74.7 million, an increase from RMB 73.5 million in 2023[16]. - The net loss for the year ended December 31, 2024, was approximately RMB 32.6 million, compared to a net loss of RMB 13.6 million for the year ended December 31, 2023[16]. - The company's gross profit decreased by approximately 17.4% to about RMB 27.0 million, with a gross margin of approximately 36.1%, down from 44.4% in the previous fiscal year[36]. - Other income and gains decreased by approximately 27.1% to about RMB 4.3 million, mainly due to reduced bank interest income[37]. - Administrative expenses increased by approximately 60.3% to about RMB 36.7 million, primarily due to share-based compensation for senior management and costs related to acquisitions[39]. - The company recorded a loss attributable to owners of approximately RMB 32.4 million for the reporting period, compared to a loss of RMB 13.6 million in the previous fiscal year[41]. Patient Metrics - The number of active dental patients increased from 50,324 to 61,777 during the year[11]. - The total number of active patients increased by 22.8%, from 50,324 in 2023 to 61,777 in 2024[22]. - The number of active patients at Wenzhou Hospital increased from 27,958 in 2023 to 28,366 in 2024[22]. - The dental service provider maintains a patient acceptance rate of 68% in Wenzhou, higher than the national average of 52%[10]. Operational Strategy - The company aims to enhance medical technology and service quality in response to upcoming dental pricing reforms announced by the National Medical Insurance Bureau[11]. - Future plans include focusing on precise diagnosis and personalized treatment solutions, as well as building a smart training platform for professional talent[12]. - The company intends to deepen cooperation with international medical institutions while expanding into overseas markets[12]. - The group plans to optimize its cost structure and improve operational efficiency to attract price-sensitive patients amid increased competition and regulatory changes[17]. - The group is strategically investing in scalable technologies and standardized processes to enhance its ability to provide value-oriented solutions in a changing regulatory environment[25]. - The group aims to innovate its service offerings by integrating advanced technologies, such as AI-driven diagnostics and minimally invasive treatment options[27]. Employee Metrics - The total number of employees increased to 372 as of December 31, 2024, up from 286 as of December 31, 2023, reflecting a growth in workforce[48]. - Employee benefit expenses for the reporting period were approximately RMB 522 million, an increase of RMB 188 million compared to RMB 334 million in the previous fiscal year[48]. - The employee turnover rate for the reporting period is 62%, which is considered slightly high within the industry[198]. - Female employees account for over 75% of the workforce, highlighting the company's commitment to gender equality in hiring and promotion practices[197]. - The total number of employees by age group includes 129 under 25, 118 between 26 and 35, 73 between 36 and 45, 27 between 46 and 55, and 25 aged 56 and above[197]. Corporate Governance - The board of directors is committed to maintaining high standards of corporate governance and business ethics[76]. - The board has established three committees: Audit Committee, Remuneration Committee, and Nomination Committee to oversee specific aspects of the company's affairs[81]. - The company has adopted the standard code of conduct for directors' securities transactions during the reporting period[79]. - The board believes that the risk management and internal control systems are effective and sufficient during the reporting period[130]. - The company has established a mechanism to ensure independent viewpoints are obtained for board decisions, including the review of the proportion and contributions of independent non-executive directors[103]. Environmental, Social, and Governance (ESG) Initiatives - The group emphasizes sustainable development and corporate social responsibility while balancing profitability, environmental, and social impacts[152]. - The group adheres to the Hong Kong Stock Exchange's ESG reporting guidelines, focusing on materiality, quantification, balance, and consistency[155]. - The board is responsible for overseeing ESG-related risks and opportunities, setting strategies, and reviewing performance annually[161]. - The group has identified key environmental, social, and governance issues that may impact its sustainable development, conducting a materiality assessment to evaluate their significance[171]. - The company emphasizes the importance of environmental sustainability and aims to reduce negative impacts on the environment while contributing to sustainable development[175]. Future Plans and Investments - The company plans to consolidate and expand its market position in China[82]. - The company aims to expand its global dental care network and establish chain dental clinics under a new brand name outside Wenzhou[87]. - The company plans to purchase new dental equipment and supplies to enhance the quality of dental services provided[87]. - A dental training center will be established to build a talent pool of dentists and improve service quality[87]. - The company has not established an internal audit function, considering the scale and complexity of its operations[129].

Financial Performance - Revenue increased by approximately 1.6% to about RMB 74.7 million for the year ending December 31, 2024, compared to RMB 73.5 million for the year ending December 31, 2023[4] - Loss before tax was approximately RMB 30.1 million, worsening from a loss of approximately RMB 7.2 million for the year ending December 31, 2023[4] - Loss attributable to equity holders of the company was approximately RMB 32.4 million, compared to a loss of approximately RMB 13.6 million for the year ending December 31, 2023[4] - Basic and diluted loss per share attributable to ordinary equity holders of the parent was approximately RMB 5.57 cents, compared to RMB 2.27 cents for the year ending December 31, 2023[4] - Total comprehensive loss for the year was RMB 31.146 million, compared to RMB 12.206 million for the previous year[6] - The group reported a pre-tax loss of RMB 49,280,000 for 2024, compared to RMB 32,074,000 in 2023, indicating an increase in losses[24] - The net loss for the fiscal year ending December 31, 2024, was approximately RMB 32.6 million, compared to a net loss of RMB 13.6 million for the fiscal year ending December 31, 2023, indicating a significant increase in losses[39] Revenue Breakdown - Revenue from customer contracts for 2024 was RMB 74,680,000, an increase of 1.6% from RMB 73,513,000 in 2023[21] - Revenue for the reporting period was approximately RMB 74.7 million, an increase of about 1.6% compared to the fiscal year ending December 31, 2023, primarily due to contributions from two new facilities[54] - Revenue from the Oral Comprehensive Treatment Department was approximately RMB 30.5 million, a decrease of about 2.2% compared to the previous fiscal year, accounting for approximately 40.8% of total revenue[55] - Revenue from the Orthodontics Department was approximately RMB 14.1 million, a decrease of about 2.1% compared to the previous fiscal year, representing about 18.9% of total revenue[56] - Revenue from the Oral Rehabilitation Department was approximately RMB 16.3 million, an increase of RMB 1.4 million, accounting for about 21.8% of total revenue[57] - Revenue from the Implant Dentistry Department was approximately RMB 8.9 million, an increase of about 11.3% compared to the previous fiscal year, indicating a recovery in revenue[58] Expenses and Costs - Gross profit decreased to RMB 26.976 million from RMB 32.655 million, reflecting a decline in profitability[6] - Administrative expenses increased significantly to RMB 36.733 million from RMB 22.940 million, indicating rising operational costs[6] - Sales costs increased by approximately 16.6% to about RMB 47.7 million, attributed to rising employee costs and stock issuance rewards[59] - Selling expenses increased by approximately 10.1% to about RMB 22.8 million, mainly due to increased marketing and promotional expenses[62] - Employee benefits expenses increased to approximately RMB 52.2 million during the reporting period, compared to approximately RMB 33.4 million in the fiscal year 2023, an increase of RMB 18.8 million[72] Assets and Liabilities - Non-current assets increased to RMB 91,889 thousand in 2024 from RMB 80,117 thousand in 2023, representing a growth of 14.5%[8] - Current assets decreased to RMB 98,265 thousand in 2024 from RMB 152,310 thousand in 2023, a decline of 35.5%[8] - Total liabilities increased to RMB 69,756 thousand in 2024 from RMB 66,882 thousand in 2023, reflecting a rise of 4.2%[9] - The company's net asset value decreased to RMB 120,398 thousand in 2024 from RMB 165,545 thousand in 2023, a drop of 27.2%[9] - Cash and cash equivalents decreased to RMB 78,494 thousand in 2024 from RMB 86,827 thousand in 2023, a reduction of 9.5%[8] - The company reported a total equity of RMB 120,398 thousand in 2024, down from RMB 165,545 thousand in 2023, indicating a decrease of 27.2%[9] Taxation - The group's income tax expense for the fiscal year 2024 was RMB 2,478 thousand, a decrease from RMB 6,448 thousand in 2023[29] - The group has no income tax liabilities in Hong Kong for the fiscal year 2024 due to no taxable profits generated[8] - The group has a deferred tax expense of RMB 459 thousand for the fiscal year 2024, down from RMB 4,511 thousand in 2023[29] Corporate Governance and Shareholder Information - The board has resolved not to recommend the payment of a final dividend for the year ending December 31, 2024, compared to a dividend of HKD 0.01 per share for the year ending December 31, 2023[4] - The annual general meeting is scheduled for June 18, 2025, with a suspension of share transfer registration from June 13 to June 18, 2025[82][83] - The company has complied with all corporate governance codes applicable as of December 31, 2024, except for one specific provision[84] - The audit committee consists of three independent non-executive directors, who have reviewed the annual consolidated financial statements for the year ending December 31, 2024[89] Strategic Initiatives - The group is adjusting its business to respond to the national dental procurement policy, which has expanded to orthodontics, pediatric dentistry, and cosmetic dentistry[49] - The group aims to optimize its service offerings and strengthen partnerships with upstream suppliers to maintain service quality while achieving cost efficiency[49] - The group plans to enhance community-centered initiatives, including expanding oral health education programs and supporting vulnerable groups in collaboration with local governments[50] - The group is committed to reducing waste in clinical operations and promoting digital patient engagement tools[50] - The group is strategically investing in scalable technologies and standardized processes to ensure adaptability in a rapidly changing regulatory environment[49] - The group is focused on optimizing its cost structure to attract price-sensitive patients while ensuring service quality[41] - The group is establishing long-term partnerships with dental material suppliers to obtain better purchasing prices and improve internal management efficiency[41]

美 皓 醫 療 集 團 有 限 公 司（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，本 公 司 將 於 二 零 二 五 年 三 月 二 十 八 日（星 期 五）舉 行 董 事 會 會 議，藉 以（其 中 包 括）考 慮 及批准本公司及其附屬公司截至二零二四年十二月三十一日止年度之年度業 績 及 其 刊 發，以 及 考 慮 建 議 派 發 末 期 股 息（如 有）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Meihao Medical Group Co., Ltd 美皓醫療集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1947） 董事會會議日期 承董事會命 美皓醫療集團有限公司 主席兼執行董事 王曉敏 香 港，二 零 二 五 年 三 月 十 二 日 於 本 公 告 日 期，執 行 董 事 為 ...

美皓醫療集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1947） 盈利警告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 不 會 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Meihao Medical Group Co., Ltd (i) 持 續 受 到 種 植 牙 集 採 政 策 影 響，銷 售 價 格 大 幅 度 降 低，進 一 步 縮 減 植 牙 服 務 的 利 潤 空 間； (ii) 本 地 口 腔 市 場 競 爭 激 烈，行 業 內 的 價 格 戰 和 過 度 競 爭 加 劇 了 盈 利 壓 力，導 致 新 客 戶 開 發 成 本 變 高，缺 乏 有 效 的 客 源 渠 道，且 轉 化 率 不 穩 定； 儘 管 現 況 如 此，本 集 團 仍 保 持 了 良 好 財 務 狀 況，公 司 現 金 儲 備 充 足。董 事 會 將 繼 續 評 估 具 有 挑 戰 ...

Meihao Medical Group Co., Ltd 美皓醫療集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1947） 董事名單與其角色職能 美 皓 醫 療 集 團 有 限 公 司（「本公司」）董 事（「董 事」）會（「董事會」）成 員 載 列 如 下： 執行董事 王曉敏先生 （主 席） 鄭蠻女士 周健醫生 獨立非執行董事 譚漢珊女士 張永存先生 董 事 會 下 設 三 個 委 員 會，該 等 委 員 會 的 成 員 載 列 如 下： | | 董事委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | --- | | 董 事 | | | | | | 王曉敏先生 | | – | M | C | | 鄭蠻女士 | | – | – | – | | 周健醫生 | | – | – | – | | 黃晞華先生 | | C | M | – | | 譚漢珊女士 | | M | C | M | | 張永存先生 | | M | – | M | 附 註： C: 有關董事委員會的主席 M: 有關董事委員會的成員 香 港，二 零 二 四 年 十 一 月 二 十 ...

Meihao Medical Group Co., Ltd 美皓醫療集團有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 （股份代號：1947） （於開曼群島註冊成立的有限公司） (1)董 事 調 任； (2)委 任 獨 立 非 執 行 董 事； 及 (3)審核委員會及提名委員會成員變動 (1) 董事調任 美 皓 醫 療 集 團 有 限 公 司（「本公司」，連 同 附 屬 公 司 統 稱「本集團」）董 事（「董 事」）會（「董事會」）欣 然 宣 佈，自 二 零 二 四 年 十 一 月 二 十 九 日 起，周 健 醫 生 （「周醫生」）已 由 獨 立 非 執 行 董 事 調 任 為 執 行 董 事，並 不 再 為 本 公 司 審 核 委 員 會（「審核委員會」）成 員 及 本 公 司 提 名 委 員 會（「提名委員會」）成 員。 周 醫 生 的 履 歷 詳 情 如 下： 周 醫 生，69歲 ...